TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21869699

Group type: EXPERIMENTAL
Intervention: Aripiprazole 2.5 mg/d plus sertraline 50 mg/d
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo plus sertraline 50 mg/d
Number of subjects: 41
Study: 19424038

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (TMG)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Basiliximab (BAS)
Number of subjects: 278
Study: 17763106

Group type: EXPERIMENTAL
Intervention: Assisted self-help (manual + videotape + two supportive phone calls)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Manual only (self-help manual)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Quitting on one's own (no intervention)
Number of subjects: 1069
Study: 15194981

Group type: EXPERIMENTAL
Intervention: Clopidogrel with loading dose
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Clopidogrel without loading dose
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Clopidogrel (overall)
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Death or non-fatal myocardial infarction
Number of subjects: 2962
Study: 15381441

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy with a body exposure component (CBT-E)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy with a cognitive restructuring component focused on body image (CBT-C)
Number of subjects: 28
Study: 10968328

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg orally, once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clarithromycin (500 mg orally, twice daily)
Number of subjects: 12
Study: 9050956

Group type: EXPERIMENTAL
Intervention: Continuous intrathecal baclofen infusion (CIBI)
Number of subjects: 18
Study: 8378900

Group type: EXPERIMENTAL
Intervention: High dose Curosurf (200 mg/kg initial dose, up to five doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low dose Curosurf (100 mg/kg initial dose, up to three doses)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Babies with birthweight < 750 grams or gestational age < 26 weeks
Number of subjects: 43
Study: 3718621

Group type: EXPERIMENTAL
Intervention: TAC (tetracaine, adrenaline, and cocaine)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Tetracaine
Number of subjects: 68
Study: 29587530

Group type: EXPERIMENTAL
Intervention: Sleep problems
Number of subjects: 240
Study: 29335791

Group type: EXPERIMENTAL
Intervention: Dexamethasone (30 mg total dose, perioperatively)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no glucocorticoid)
Number of subjects: 73
Study: 27595690

Group type: EXPERIMENTAL
Intervention: Moderate physical activity (PA) intervention for 1 year
Number of subjects: 307

Group type: COMPARATOR
Intervention: Health education control for 1 year
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Moderate physical activity (PA) intervention
Number of subjects: 307

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 307
Study: 25128485

Group type: EXPERIMENTAL
Intervention: Antenatal self-administration of unfractionated heparin (UFH) 7500 IU twice-daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 32
Study: 23247713

Group type: EXPERIMENTAL
Intervention: 1 d of GTE ingestion (GTE1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 7 d of GTE ingestion (GTE7)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (7 d)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Placebo (6 d) followed by 1 d of GTE (GTE1)
Number of subjects: 31
Study: 21436923

Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) services provided by third-year pharmacy students
Number of subjects: 0
Study: 18841288

Group type: EXPERIMENTAL
Intervention: Tirofiban (bolus of 10 microg/kg body weight followed by continued infusion of 0.15 microg/kg body weight per minute)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 600 mg clopidogrel and acetylsalicylic acid (ASA)
Number of subjects: 100
Study: 17126650

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg 2 times daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12792289

Group type: EXPERIMENTAL
Intervention: Isoflavones (110 mg total per day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (inert ingredients)
Number of subjects: 56
Study: 10320160

Group type: EXPERIMENTAL
Intervention: Aggressive insulin therapy (AIT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard insulin therapy (SIT)
Number of subjects: 26
Study: 9499812

Group type: EXPERIMENTAL
Intervention: Capsaicin during upper respiratory infection (URI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (26 subjects without URI)
Number of subjects: 31
Study: 1838916

Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg + Hydrochlorothiazide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cilazapril + Hydrochlorothiazide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study: 6842002

Group type: EXPERIMENTAL
Intervention: Selective antimicrobial modulation (SAM) regimen
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30908852

Group type: EXPERIMENTAL
Intervention: Ex vivo fluorescence confocal microscopy (FCM)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Histopathological diagnoses (gold standard)
Number of subjects: 13
Study: 28213566

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 150 mg
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 30 mg
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 25643304

Group type: EXPERIMENTAL
Intervention: Energy-dense, protein-rich oral formula enriched with arginine, zinc, and antioxidants (400 mL/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous formula
Number of subjects: 200
Study: 24004451

Group type: EXPERIMENTAL
Intervention: Yukmijihwang-tang administered for 8 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo administered for 8 weeks
Number of subjects: 96
Study: 21880799

Group type: EXPERIMENTAL
Intervention: Low-dose daily oral E(2) (0.5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose transdermal E(2) (0.0375 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose oral E(2) (2.0 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose transdermal E(2) (0.075 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transdermal E(2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral E(2) (low or high dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LH and FSH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IGF-I concentrations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein/high-density lipoprotein cholesterol responses
Number of subjects: 30
Study: 18854202

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice, immediate start
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transcendental Meditation (TM) practice, delayed start
Number of subjects: 50
Study: 17638595

Group type: EXPERIMENTAL
Intervention: autoCPAP devices
Number of subjects: 83

Group type: COMPARATOR
Intervention: fixed pressure CPAP
Number of subjects: 83
Study: 15170933

Group type: EXPERIMENTAL
Intervention: Comprehensive Osteoarthritis Test (COAT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Number of subjects: 125
Study: 12077039

Group type: EXPERIMENTAL
Intervention: NT‐proBNP assay in the general population (population screen)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: NT‐proBNP assay in patients from the three other populations screened
Number of subjects: 591
Study: 9804601

Group type: EXPERIMENTAL
Intervention: PSV (Pressure Support Ventilation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PAV (Proportional Assist Ventilation)
Number of subjects: 12
Study: 10155734

Group type: EXPERIMENTAL
Intervention: Combination of immunosuppressive drugs and therapeutic plasma exchange (TPE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immunosuppressive drugs only (Control)
Number of subjects: 24
Study: 2521184

Group type: EXPERIMENTAL
Intervention: GR38032F 0.18 mg/kg every 2 hours (trial 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GR38032F 0.04 mg/kg every 2 hours (trial 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GR38032F 0.15 mg/kg every 2 hours (trial 3)
Number of subjects: 40
Study: 630905

Group type: EXPERIMENTAL
Intervention: 2% miconazole cream
Number of subjects: 50

Group type: COMPARATOR
Intervention: nystatin pessaries
Number of subjects: 50
Study: 6127970

Group type: EXPERIMENTAL
Intervention: Intramuscular dihydrocodeine
Number of subjects: 181

Group type: COMPARATOR
Intervention: Caudal bupivacaine
Number of subjects: 181
Study: 31260792

Group type: EXPERIMENTAL
Intervention: iChoose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family Connections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29708766

Group type: EXPERIMENTAL
Intervention: Combined MTrP therapy and stretching plus suboccipital soft tissue inhibition
Number of subjects: 46

Group type: COMPARATOR
Intervention: Combined MTrP therapy and stretching (control group)
Number of subjects: 46
Study: 26644304

Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Non-exercise control activity
Number of subjects: 186
Study: 24874285

Group type: EXPERIMENTAL
Intervention: Treatment change (start or change of adjuvant endocrine agent)
Number of subjects: 85

Group type: COMPARATOR
Intervention: No change (control)
Number of subjects: 85
Study: 22230143

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-IPT (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 200
Study: 20845089

Group type: EXPERIMENTAL
Intervention: Developed morphine sulfate sustained-release tablets
Number of subjects: 15

Group type: COMPARATOR
Intervention: Commercial brand of morphine sulfate sustained-release tablets
Number of subjects: 15
Study: 17716287

Group type: EXPERIMENTAL
Intervention: Dardia Lipo Line (Intendis GmbH, Berlin, Germany)
Number of subjects: 0
Study: 15217841

Group type: EXPERIMENTAL
Intervention: Weekly home visits by community health aides for one year in addition to usual duties
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual duties
Number of subjects: 139
Study: 11515711

Group type: EXPERIMENTAL
Intervention: Clarithromycin formulation 1 (250 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clarithromycin formulation 2 (250 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Clarithromycin formulation 1 and 2
Number of subjects: 24
Study: 9061169

Group type: EXPERIMENTAL
Intervention: Allogeneic human bone grafts
Number of subjects: 21
Study: 8113479

Group type: EXPERIMENTAL
Intervention: Time-limited psychodynamically oriented treatments (12 sessions)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Time-unlimited psychodynamically oriented treatments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Minimal-contact control group
Number of subjects: 30
Study: 3533834

Group type: EXPERIMENTAL
Intervention: Fentanyl (100 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (7.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28074672

Group type: EXPERIMENTAL
Intervention: Power-assisted exercise intervention (three times a week for thirty minutes over a twenty-week period)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 37
Study: 26253730

Group type: EXPERIMENTAL
Intervention: Prandial Technosphere inhaled insulin (TI)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Prandial Technosphere inhaled placebo (TP)
Number of subjects: 353
Study: 25612894

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg/d)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Amisulpride (200 mg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 21602259

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diet + fenofibrate
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diet + rimonabant
Number of subjects: 46
Study: 18775050

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (ablation)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 70
Study: 17576402

Group type: EXPERIMENTAL
Intervention: Misgav Ladach method
Number of subjects: 111

Group type: COMPARATOR
Intervention: Pfannenstiel method
Number of subjects: 111
Study: 15274068

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (home-based, moderate-intensity walking)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (advice to rest)
Number of subjects: 66
Study: 11285152

Group type: EXPERIMENTAL
Intervention: 4-day parenteral beta-lactam therapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: 7-day parenteral beta-lactam therapy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 154
Study: 9483391

Group type: EXPERIMENTAL
Intervention: Caffeine (loading dose 10 mg/kg followed by 5 mg/kg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Theophylline (loading dose 4 mg/kg followed by 4 mg/kg/day)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 53
Study: 8148229

Group type: EXPERIMENTAL
Intervention: ICI 192605 (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 8
Study: 3162905

Group type: EXPERIMENTAL
Intervention: Enoxacin (single dose or three divided doses)
Number of subjects: 27
Study: 31235709

Group type: EXPERIMENTAL
Intervention: Su-Wang technique (S-W)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Jaboulay's procedure (JA)
Number of subjects: 42
Study: 27720917

Group type: EXPERIMENTAL
Intervention: THC tablet (3 mg 3 times daily for 5 days, then 5 mg 3 times daily for 5 days, followed by 8 mg 3 times daily until days 50-52)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 65
Study: 25025548

Group type: EXPERIMENTAL
Intervention: 3-min MDI video
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nutrition video (control group)
Number of subjects: 91
Study: 23363480

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program focusing on learning about brain functions and influences on cognition
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cognitive rehabilitation program adopting a top-down approach to improve abstract reasoning abilities
Number of subjects: 100
Study: 21875845

Group type: EXPERIMENTAL
Intervention: Avoidant coping style
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Emotion-focused coping style
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Instrumental coping style
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host disease
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Breathing symptoms
Number of subjects: 105
Study: 19369445

Group type: EXPERIMENTAL
Intervention: Self-collected glans swab specimens (method 1 and method 2)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Self-collected rectal swab specimens
Number of subjects: 882

Group type: COMPARATOR
Intervention: Clinician-collected rectal swab specimens
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: AC2 and SDA tests
Number of subjects: 882
Study: 17462550

Group type: EXPERIMENTAL
Intervention: SVLPD (0.3 g/kg/d of vegetable proteins and ketoanalogues, 1 capsule for every 5 kg of ideal body weight per day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional low mixed protein diet (0.6 g/kg/d)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: SVLPD
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional low mixed protein diet
Number of subjects: 53
Study: 15466617

Group type: EXPERIMENTAL
Intervention: Turkish version of the Exercise of Self-Care Agency Scale (ESCA)
Number of subjects: 119

Group type: COMPARATOR
Intervention: English version of the Exercise of Self-Care Agency Scale (ESCA)
Number of subjects: 119
Study: 11562580

Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circulation with full dose systemic heparinization (Group B)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circulation with low dose systemic heparinization (Group C)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Uncoated extracorporeal circulation with full dose systemic heparinization (Group A)
Number of subjects: 119
Study: 9690594

Group type: EXPERIMENTAL
Intervention: Mepivacaine (IVRA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 16
Study: 7907732

Group type: EXPERIMENTAL
Intervention: Insecticide spraying of the child's dwelling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2683545

Group type: EXPERIMENTAL
Intervention: CHFV (combination of continuous positive pressure ventilation and high frequency ventilation)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CHFV
Number of subjects: 47

Group type: COMPARATOR
Intervention: CPPV (control group)
Number of subjects: 47
Study: 31509018

Group type: EXPERIMENTAL
Intervention: Stable trait of sensation seeking
Number of subjects: 552
Study: 30103216

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (single dose and multiple doses for 24 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (multiple doses for 24 weeks)
Number of subjects: 0
Study: 29227124

Group type: EXPERIMENTAL
Intervention: Coached group (given information about ADHD symptoms)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Noncoached group (given no additional information)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Genuine ADHD group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nonclinical group (asked to respond honestly)
Number of subjects: 2
Study: 26283139

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase (0.6 mg/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose intravenous alteplase (0.9 mg/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure lowering (systolic target 130-140 mmHg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure control (systolic target <180 mmHg)
Number of subjects: 0
Study: 23818039

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (LM group)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (MH group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (PP group)
Number of subjects: 165
Study: 21600676

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention programme centered on the regulation of emotions
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 19627532

Group type: EXPERIMENTAL
Intervention: US-guided ilioinguinal nerve block with 0.1 ml x kg(‐1) of 0.25% bupivacaine with 1 : 200,000 epinephrine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-shot caudal block with 0.7 ml x kg(‐1) of 0.125% bupivacaine with 1 : 200,000 epinephrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: US-guided ilioinguinal nerve block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-shot caudal block
Number of subjects: 50
Study: 17101847

Group type: EXPERIMENTAL
Intervention: RB006 (anticoagulant)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: RB007 (antidote)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 15561322

Group type: EXPERIMENTAL
Intervention: Telmisartan 40-80 mg once daily for 1 year
Number of subjects: 85
Study: 11731185

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg) for 21 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg) for 11 days and cyproterone acetate (1 mg) for 10 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Estradiol valerate alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Estradiol valerate in association with cyproterone acetate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Estradiol valerate alone or in association with cyproterone acetate
Number of subjects: 20
Study: 9530055

Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Catheter drainage
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study: 1882895

Group type: EXPERIMENTAL
Intervention: Sucralfate tablets, 4 g/day for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cimetidine, 1.6 g/day for 8 weeks
Number of subjects: 48
Study: 6346962

Group type: EXPERIMENTAL
Intervention: Flunisolide aerosol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30902422

Group type: EXPERIMENTAL
Intervention: Muscular strength (measured by handgrip strength)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Speed-agility
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness and overall fitness Z-score
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physical activity and sedentary time
Number of subjects: 100
Study: 29110518

Group type: EXPERIMENTAL
Intervention: Age-appropriate preparation for children undergoing RT
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (standard preparation)
Number of subjects: 33
Study: 27028832

Group type: EXPERIMENTAL
Intervention: Ketamine administered via intravenous (IV) route
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketamine administered via intramuscular (IM) route
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ketamine administered via subcutaneous (SC) route
Number of subjects: 15

Group type: COMPARATOR
Intervention: Midazolam (control treatment)
Number of subjects: 15